SKYE
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Skye receives approval to open Cohort 2 after favorable safety data from the first participants in Cohort 1May 20, 2026
- Skye Bioscience dosed the first patient in higher-dose nimacimab expansion study to guide Phase 2b dosingApr 2, 2026
- Skye reported positive CBeyond Phase 2a extension results for nimacimab with semaglutideFeb 2, 2026
- Skye Bioscience reports topline CBeyond™ Phase 2a data from Nimacimab monotherapy and combination clinical trialOct 6, 2025
- Skye presents Phase 1b data for its peripheral CB1-inhibiting antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) annual meetingSep 19, 2025